Marshall Wace, LLP Entrada Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 65,943 shares of TRDA stock, worth $1.13 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,943
Previous 51,723
27.49%
Holding current value
$1.13 Million
Previous $732,000
28.28%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding TRDA
# of Institutions
85Shares Held
27.7MCall Options Held
100Put Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$83.1 Million0.92% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$75.5 Million34.63% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$75.3 Million29.39% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.13MShares$53.5 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$28.9 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $535M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...